NEW YORK (dpa-AFX Broker) - JPMorgan has downgraded Evonik from 'Neutral' to 'Underweight', maintaining a price target of 14 euros. 'The industry blues appear to be returning,' wrote analyst Chetan Udeshi on Thursday following his review of the European chemicals sector. While the duration of the conflict in the Middle East remains difficult to gauge, recent data suggests that the short-term tailwinds resulting from its disruptions may be weaker than anticipated and are likely already tapering off. Consequently, investors should not overstate the importance of the second quarter, as a weak second half and the outlook for 2027 bring the sector's structural issues back into focus: massive overcapacity and intensifying competition in specialty products from China and the rest of Asia./ag/zb

Original study published: 21.05.2026 / 23:12 / BST

Original study first disseminated: 22.05.2026 / 00:15 / BST

-----------------------

dpa-AFX Broker - Trader News from dpa-AFX

-----------------------